ADAPT Phase 3 Clinical Trial
The ADAPT Kidney Cancer Study is a randomized, multi-center, open-label clinical trial and is designed to examine the potential for AGS-003 plus standard targeted drug therapy to extend overall survival versus standard therapy alone in newly diagnosed patients with unfavorable risk metastatic renal cell carcinoma (mRCC).
This ongoing pivotal study is expected to enroll 450 patients across approximately 140 sites, in North America, Europe and Israel. For more information about AGS-003 and the ongoing ADAPT study, visit www.ADAPTkidneycancer.com.
AGS-004 Phase 2b Trial for HIV
For more information, visit http://clinicaltrials.gov/ct2/show/NCT01069809?term=AGS-004&rank=2.